StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Iovance Biotherapeutics's enterprise value was $3.37B on Nov 11, 2026, against $651.29M a year earlier. Over the last 5 years it ranged from $214.65M to $6.42B, with a median of $1.27B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$3.37B+348.0%
2025Dec 31, 2025$751.51M-59.5%
2024Dec 31, 2024$1.86B+8.0%
2023Dec 29, 2023$1.72B+164.8%
2022Dec 30, 2022$649.43M-73.1%
2021Dec 31, 2021$2.42B-60.3%
2020Dec 31, 2020$6.08B+94.2%
2019Dec 31, 2019$3.13B+358.5%
2018Dec 31, 2018$682.96M+65.7%
2017Dec 29, 2017$412.24M+64.1%
2016Dec 30, 2016$251.24M-3.0%
2015Dec 31, 2015$258.93M+29.2%
2014Dec 31, 2014$200.33M+26.7%
2013Dec 31, 2013$158.14M+818.1%
2012Dec 31, 2012$17.22M-76.6%
2011Dec 30, 2011$73.51M–

More Iovance Biotherapeutics figures

See a number that looks wrong?